



State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: July 2, 2021

TO: All Louisiana Medicaid Prescribing Providers and Pharmacists

FROM: Tara A. LeBlanc, Interim Medicaid Executive Director *Tara A. LeBlanc*

SUBJECT: Louisiana Medicaid Manual Review Authorization for Aduhelm™
(aducanumab-avwa)

Aduhelm™ (aducanumab-avwa) is a new drug indicated for the treatment of Alzheimer's disease and is administered via intravenous infusion. Aduhelm™ was approved using the FDA's accelerated approval pathway. Under the accelerated approval provisions, the FDA is requiring the drug manufacturer to conduct a new randomized, controlled clinical trial to verify the drug's clinical benefit.

Based on the currently available efficacy and safety information for this drug, Louisiana Medicaid has determined that the lack of an authorization process would pose an imminent peril to beneficiaries. Therefore, Louisiana Medicaid is implementing manual prior authorization for this drug until such time as sufficient data are available to develop clinical criteria. The effective date for this requirement is June 23rd, 2021.

Authorization requests submitted through the manual review process will be evaluated on a case-by-case basis. The prescriber must submit a letter explaining the medical necessity of the medication and submit documentation to support the use of the medication for the beneficiary.